Conestoga Small Cap Fund


News and Press

September 5, 2016: Conestoga Capital Advisors and the Conestoga Funds were featured in a recent article in Barron’s. Bob Mitchell and Joe Monahan, Co-Portfolio Managers, discuss their views on the firm’s investment approach for the Conestoga Funds. The article may be accessed directly from Barron’s via the link below:


IMPORTANT DISCLOSURE INFORMATION:

Total Returns of the Conestoga Small Cap Fund (CCASX) as of June 30, 2016*

  QTD YTD 1 Year 3 Years 5 Years 10 Years Inception
10/1/2002
CCASX 5.74% 2.07% 1.64% 9.11% 9.40% 8.38% 10.89%
Russell 2000 Growth 3.24% -1.59% -10.75% 7.74% 8.51% 7.14% 10.54%
Russell 2000 3.79% 2.22% -6.73% 7.09% 8.35% 6.20% 10.11%

* Performance is based upon closing NAV calculation on listed dates and represents past performance. Past performance does not guarantee future results and current performance may be lower or higher than the performance quoted. Performance data includes reinvestment of dividends. Investment returns and principal value of an investment in the Conestoga Small Cap Fund will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. For the Fund’s daily NAV, list of additional holdings, total return as of the most recent month-end, and a copy of the Fund’s prospectus, please visit www.conestogacapital.com or call 1-800-494-2755.

IMPORTANT INFORMATION FOR INVESTORS

The Conestoga Small Cap Fund’s (CCASX) Gross Expense ratio: 1.50%; Net Expense ratio: 1.10%. These are expenses that you pay each year as a percentage of the value of your investments. Conestoga Capital Advisors, LLC (the Adviser) has contractually agreed to limit the Fund’s net annual operating expenses to 1.10% of the Fund’s average daily net assets until at least January 31, 2017, subject to termination at anytime at the option of the Fund. There is no guarantee that the agreement to limit the Fund’s net annual operating expense will be renewed or extended. The Top Ten Holdings in the Conestoga Small Cap Fund as of June 30, 2016 are as follows: 1. Omnicell Inc. (3.72%); 2. Mesa Labs Inc. (3.26%); 3. Vascular Solutions Inc. (3.22%); 4. SPS Commerce Inc. (3.22%); 5. Neogen Corp. (3.20%); 6. Blackbaud Inc. (3.20%); 7. Cantel Medical Corp. (3.05%); 8. Tyler Technologies Inc. (2.92%); 9. Dorman Products Inc. (2.83); 10. AAON Inc. (2.80%). The Russell 2000 Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted growth values. Russell 2000 Index is an index that measures the performance of the 2,000 smallest companies in the Russell 3000 Index. An individual cannot invest directly in an index.The thoughts and opinions expressed in the interview are those of the speakers as of August 2016. The discussion of individual companies should not be considered a recommendation of such companies by the Fund’s investment adviser. The discussion is designed to provide a reader with an understanding of how the Fund’s investment adviser manages the Fund’s portfolio. There can be no assurance with regard to future market movements. Mutual fund investing involves risk. Principal loss is possible. The Fund may invest in small- and mid-cap companies, which involves additional risks such as limited liquidity and greater volatility. The Fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The prospectus contains this and other important information about the Fund and may be obtained by calling 1-800-494-2755. Read it carefully before investing. Distributed by Ultimus Fund Distributors, LLC.